Zhanhong Wu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4085054/publications.pdf

Version: 2024-02-01

218677 168389 2,891 54 26 53 h-index citations g-index papers 55 55 55 3707 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Synthesis and Initial Evaluation of MerTK Targeted PET Agents. Molecules, 2022, 27, 1460.	3.8	O
2	Arene radiofluorination enabled by photoredox-mediated halide interconversion. Nature Chemistry, 2022, 14, 216-223.	13.6	25
3	Biodistribution of Biomimetic Drug Carriers, Mononuclear Cells, and Extracellular Vesicles, in Nonhuman Primates. Advanced Biology, 2022, 6, e2101293.	2.5	7
4	Development of ¹⁸ F-Labeled Vinyl Sulfone–PSMAi Conjugates as New PET Agents for Prostate Cancer Imaging. Molecular Pharmaceutics, 2022, 19, 720-727.	4.6	3
5	Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging. Journal of Medicinal Chemistry, 2021, 64, 5593-5602.	6.4	9
6	Image-guided selection of Gd@C-dots as sensitizers to improve radiotherapy of non-small cell lung cancer. Journal of Nanobiotechnology, 2021, 19, 284.	9.1	16
7	A Novel PET Probe for Brown Adipose Tissue Imaging in Rodents. Molecular Imaging and Biology, 2020, 22, 675-684.	2.6	8
8	Escalating morphine dosing in HIV-1 Tat transgenic mice with sustained Tat exposure reveals an allostatic shift in neuroinflammatory regulation accompanied by increased neuroprotective non-endocannabinoid lipid signaling molecules and amino acids. Journal of Neuroinflammation, 2020, 17, 345.	7.2	13
9	RXH-Reactive ¹⁸ F-Vinyl Sulfones as Versatile Agents for PET Probe Construction. Bioconjugate Chemistry, 2020, 31, 2482-2487.	3.6	10
10	19F- and 18F-arene deoxyfluorination via organic photoredox-catalysed polarity-reversed nucleophilic aromatic substitution. Nature Catalysis, 2020, 3, 734-742.	34.4	53
11	Tetrazine-TCO Ligation: A Potential Simple Approach to Improve Tumor Uptake through Enhanced Blood Circulation. Bioconjugate Chemistry, 2020, 31, 1795-1803.	3.6	9
12	Direct Radiofluorination of Arene C–H Bonds via Photoredox Catalysis Using a Peroxide as the Terminal Oxidant. Organic Letters, 2020, 22, 7971-7975.	4.6	18
13	Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2199-2207.	6.4	11
14	Hydrophilic ¹⁸ F-labeled <i>trans</i> -5-oxocene (oxoTCO) for efficient construction of PET agents with improved tumor-to-background ratios in neurotensin receptor (NTR) imaging. Chemical Communications, 2019, 55, 2485-2488.	4.1	23
15	Direct arene C–H fluorination with ¹⁸ F ^{â^'} via organic photoredox catalysis. Science, 2019, 364, 1170-1174.	12.6	120
16	Development of Bispecific NT-PSMA Heterodimer for Prostate Cancer Imaging: A Potential Approach to Address Tumor Heterogeneity. Bioconjugate Chemistry, 2019, 30, 1314-1322.	3.6	8
17	Nanoparticleâ€Laden Macrophages for Tumorâ€Tropic Drug Delivery. Advanced Materials, 2018, 30, e1805557.	21.0	143
18	Development of [18F]AlF-NOTA-NT as PET Agents of Neurotensin Receptor-1 Positive Pancreatic Cancer. Molecular Pharmaceutics, 2018, 15, 3093-3100.	4.6	25

#	Article	IF	CITATIONS
19	The efficiency of ¹⁸ F labelling of a prostate specific membrane antigen ligand <i>via</i> strain-promoted azide–alkyne reaction: reaction speed <i>versus</i> hydrophilicity. Chemical Communications, 2018, 54, 7810-7813.	4.1	9
20	Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. Amino Acids, 2017, 49, 1325-1335.	2.7	28
21	Preparation of [18F]-NHC-BF3 conjugates and their applications in PET imaging. RSC Advances, 2017, 7, 17748-17751.	3.6	9
22	Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control. Nano Letters, 2017, 17, 862-869.	9.1	167
23	Imaging Neurotensin Receptor in Prostate Cancer With ⁶⁴ Cu-Labeled Neurotensin Analogs. Molecular Imaging, 2017, 16, 153601211771136.	1.4	17
24	Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe. Molecular Pharmaceutics, 2017, 14, 3391-3398.	4.6	18
25	Synthesis of 5-[¹⁸ F]Fluoro-α-methyl Tryptophan: New Trp Based PET Agents. Theranostics, 2017, 7, 1524-1530.	10.0	34
26	Spatial Disassociation of Disrupted Functional Connectivity for the Default Mode Network in Patients with End-Stage Renal Disease. PLoS ONE, 2016, 11, e0161392.	2.5	13
27	Synthesis and Evaluation of [¹⁸ F]â€Ammonium BODIPY Dyes as Potential Positron Emission Tomography Agents for Myocardial Perfusion Imaging. Chemistry - A European Journal, 2016, 22, 12122-12129.	3.3	30
28	Biodistribution and Radiation Dosimetry of the Enterobacteriaceae-Specific Imaging Probe [18F]Fluorodeoxysorbitol Determined by PET/CT in Healthy Human Volunteers. Molecular Imaging and Biology, 2016, 18, 782-787.	2.6	31
29	Infection Imaging With 18F-FDS and First-in-Human Evaluation. Nuclear Medicine and Biology, 2016, 43, 206-214.	0.6	51
30	Synthesis and in vivo stability studies of [¹⁸ F]-zwitterionic phosphonium aryltrifluoroborate/indomethacin conjugates. RSC Advances, 2016, 6, 23126-23133.	3.6	11
31	Synthesis and Evaluation of ⁶⁴ Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor. Molecular Pharmaceutics, 2015, 12, 3054-3061.	4.6	25
32	[¹⁸ F]–NHC–BF ₃ adducts as water stable radio-prosthetic groups for PET imaging. Chemical Communications, 2015, 51, 12439-12442.	4.1	34
33	⁶⁴ Cu Labeled Sarcophagine Exendin-4 for MicroPET Imaging of Glucagon like Peptide-1 Receptor Expression. Theranostics, 2014, 4, 770-777.	10.0	36
34	Pre-clinical evaluation of [68Ga]Ga-DO3A-VS-Cys40-Exendin-4 for imaging of insulinoma. Nuclear Medicine and Biology, 2014, 41, 471-476.	0.6	27
35	Facile Preparation of a Thiol-Reactive ¹⁸ F-Labeling Agent and Synthesis of ¹⁸ F-DEG-VS-NT for PET Imaging of a Neurotensin Receptor–Positive Tumor. Journal of Nuclear Medicine, 2014, 55, 1178-1184.	5.0	29
36	Development and Evaluation of ¹⁸ F-TTCO-Cys ⁴⁰ -Exendin-4: A PET Probe for Imaging Transplanted Islets. Journal of Nuclear Medicine, 2013, 54, 244-251.	5.0	98

#	Article	IF	CITATIONS
37	In Vivo Imaging of the Glucagonlike Peptide 1 Receptor in the Pancreas with ⁶⁸ Ga-Labeled DO3A-Exendin-4. Journal of Nuclear Medicine, 2013, 54, 1458-1463.	5.0	88
38	PET and SPECT Imaging of Tumor Proliferation. , 2012, , 219-256.		0
39	In Vivo Imaging of Transplanted Islets with ⁶⁴ Cu-DO3A-VS-Cys ⁴⁰ -Exendin-4 by Targeting GLP-1 Receptor. Bioconjugate Chemistry, 2011, 22, 1587-1594.	3.6	80
40	Fluorine-18-labeled Gd3+/Yb3+/Er3+ co-doped NaYF4 nanophosphors for multimodality PET/MR/UCL imaging. Biomaterials, 2011, 32, 1148-1156.	11.4	399
41	18F-Labeled Proteins. Current Pharmaceutical Biotechnology, 2010, 11, 572-580.	1.6	11
42	Radionuclide probes for molecular imaging of pancreatic beta-cells. Advanced Drug Delivery Reviews, 2010, 62, 1125-1138.	13.7	33
43	64Cu-Labeled PEGylated Polyethylenimine for Cell Trafficking and Tumor Imaging. Molecular Imaging and Biology, 2009, 11, 415-423.	2.6	30
44	Fluorine-18 labeled galactosyl-neoglycoalbumin for imaging the hepatic asialoglycoprotein receptor. Bioorganic and Medicinal Chemistry, 2009, 17, 7510-7516.	3.0	27
45	Dual Time Point C-11 Acetate PET Imaging Can Potentially Distinguish Focal Nodular Hyperplasia From Primary Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2009, 34, 874-877.	1.3	19
46	The Synthesis of 18F-FDS and Its Potential Application in Molecular Imaging. Molecular Imaging and Biology, 2008, 10, 92-98.	2.6	53
47	Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1489-1498.	6.4	71
48	Synthesis of a Potent and Selective $\langle \sup 18 \rangle 18 \rangle$ -Labeled \hat{l} -Opioid Receptor Antagonist Derived from the Dmt-Tic Pharmacophore for Positron Emission Tomography Imaging. Journal of Medicinal Chemistry, 2008, 51, 1817-1823.	6.4	9
49	¹⁸ F-Labeled BBN-RGD Heterodimer for Prostate Cancer Imaging. Journal of Nuclear Medicine, 2008, 49, 453-461.	5.0	132
50	microPET of Tumor Integrin ÂvÂ3 Expression Using 18F-Labeled PEGylated Tetrameric RGD Peptide (18F-FPRGD4). Journal of Nuclear Medicine, 2007, 48, 1536-1544.	5.0	120
51	64Cu-Labeled Tetrameric and Octameric RGD Peptides for Small-Animal PET of Tumor ÂvÂ3 Integrin Expression. Journal of Nuclear Medicine, 2007, 48, 1162-1171.	5.0	227
52	Click Chemistry for $\langle \sup 18 \rangle$ sup>F-Labeling of RGD Peptides and microPET Imaging of Tumor Integrin $\hat{l}_{\pm} \langle \sup \rangle \hat{l}_{\pm} \langle \sup \rangle \hat{l}_{\pm}$	3.6	139
53	18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of $\hat{l}\pm\hat{v}^2$ 3 integrin expression. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1823-1831.	6.4	119
54	Semiautomatic synthesis of $3\hat{a}\in^2$ -deoxy- $3\hat{a}\in^2$ -[18F]fluorothymidine using three precursors. Applied Radiation and Isotopes, 2006, 64, 187-193.	1,5	23